V. Parikh

发表

Discovery of hydroxamate bioisosteres as KAT II inhibitors with improved oral bioavailability and pharmacokinetics

J. Pandit, R. Obach, Ji-Young Kim, 2013 .

Synthesis of 8,9‐difluoro‐2‐methyl‐6‐oxo‐1,2‐dihydropyrrolo[3,2,1‐ij]quinoline‐5‐carboxylic acid

V. Parikh, E. Kleinman, A. Fray, 1988 .

A general strategy for the synthesis of cyclic N-aryl hydroxamic acids via partial nitro group reduction.

Ji-Young Kim, P. Verhoest, Laura A McAllister, 2011, The Journal of organic chemistry.

Structure-Based Design of Irreversible Human KAT II Inhibitors: Discovery of New Potency-Enhancing Interactions.

J. Pandit, Ji-Young Kim, P. Verhoest, 2013, ACS medicinal chemistry letters.

10 beta-propynyl-substituted steroids. Mechanism-based enzyme-activated irreversible inhibitors of estrogen biosynthesis.

D. Covey, W. Hood, V. Parikh, 1981, The Journal of biological chemistry.

Chemoproteomics demonstrates target engagement and exquisite selectivity of the clinical phosphodiesterase 10A inhibitor MP-10 in its native environment.

N. Brandon, P. Verhoest, C. J. Schmidt, 2014, ACS chemical biology.

Synthesis of ortho-substituted nitroaromatics via improved Negishi coupling conditions

Ji-Young Kim, P. Verhoest, Jaclyn L Henderson, 2011 .

Discovery of Brain-Penetrant, Irreversible Kynurenine Aminotransferase II Inhibitors for Schizophrenia.

J. Pandit, Ji-Young Kim, M. Hayward, 2012, ACS medicinal chemistry letters.

Discovery of a series of (4,5-dihydroimidazol-2-yl)-biphenylamine 5-HT7 agonists.

Anne W. Schmidt, W. M. Welch, V. Parikh, 2003, Bioorganic & medicinal chemistry letters.

Discovery and Characterization of (R)-6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Nonhuman Primates.

J. Cianfrogna, A. Stepan, Daniel P. Walker, 2017, Journal of medicinal chemistry.

Design and discovery of a selective small molecule κ opioid antagonist (2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242).

Gregory W. Kauffman, Anne W. Schmidt, S. Liras, 2011, Journal of medicinal chemistry.